ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/pan-KRAS-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/pan-KRAS-inhibitor
11
trial(s) found.
NCT07678593
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (
GFH276X0201
)
anti-EGFR monoclonal antibody
pan-RAS inhibitor,tricomplex inhibitor
+ pan-KRAS inhibitor
Cancer
Pancreatic adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - PASO Medical
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT07491445
Advanced
Phase 3
Recruiting
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma (
RASolute-303
)
antimetabolite
pan-RAS inhibitor,tricomplex inhibitor
taxane
+ pan-KRAS inhibitor
Pancreatic adenocarcinoma
Pancreatic adenosquamous carcinoma
Pancreatic cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
NCT07247110
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants With KRAS-Altered Advanced or Metastatic Solid Tumors (
4716-001
)
pan-KRAS inhibitor,undisclosed mechanism
Cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - One Clinical Research
NCT07204340
Advanced
Phase 1
Recruiting
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors (
TLN-372-2501
)
pan-KRAS inhibitor,undisclosed mechanism
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT07094113
Advanced
Phase 1
Recruiting
A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
pan-KRAS inhibitor,ON/OFF-state inhibitor
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06917079
Advanced
Phase 1
Recruiting
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers (
TBBO11818-101
)
pan-KRAS inhibitor,ON/OFF-state inhibitor
Cancer
Colorectal cancer
Lung cancer
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06884618
Advanced
Phase 1
Recruiting
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s) (
YO45758
)
pan-KRAS inhibitor,undisclosed mechanism
Cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06881784
Advanced
Phase 3
Recruiting
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC (
RASolve-301
)
pan-RAS inhibitor,tricomplex inhibitor
taxane
+ pan-KRAS inhibitor
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2217 - Kogarah - St George Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06659341
Advanced
Phase 1
Recruiting
Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors
SOS1-KRAS inhibitor
+ pan-KRAS inhibitor
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NCT06162221
Advanced
Phase 1 / Phase 2
Recruiting
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC) (
RMC-LUNG-101
)
Carboplatin
Cisplatin
Daraxonrasib
Elironrasib
HRAS inhibitor
KRAS G12C inhibitor
KRAS G12C inhibitor,tricomplex inhibitor
KRAS G12D inhibitor
KRAS G12D inhibitor,tricomplex inhibitor
KRAS inhibitor
KRAS inhibitor,ON-state
KRAS inhibitor,mutant selective
KRAS inhibitor,tricomplex inhibitor
NRAS inhibitor
Pembrolizumab
Pemetrexed
Zoldonrasib
anti-PD-1 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,KRAS-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,PD-1-targeting
pan-KRAS inhibitor
pan-RAS inhibitor
pan-RAS inhibitor,tricomplex inhibitor
platinum-based antineoplastic agent
+ pan-KRAS inhibitor
Cancer
Lung cancer
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
ACTRN12626000207314
Advanced
Phase 1
Recruiting
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 Co-Administered with a CYP3A Inhibitor in Patients with Advanced KRAS Mutant Solid Tumors (
TLN-372-2502
)
pan-KRAS inhibitor,undisclosed mechanism
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (10)
Not yet recruiting (1)
Recruitment Country and State
VIC (10)
NSW (9)
WA (5)
SA (2)
NZ (2)
QLD (1)
Phase
Phase 1 (7)
Phase 1 / Phase 2 (2)
Phase 3 (2)
Trial Type
Advanced (11)
Cancer Therapy Class
KRAS
100%
EGFR
45%
PD-1
45%
PD-1/PD-L1
45%
PI3Kalpha
9%
HRAS G12C
9%
NRAS G12C
9%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
3168 - Clayton - Monash Medical Centre (3)
3004 - Melbourne, Southbank - Alfred Health (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
2109 - North Ryde - Macquarie University Hospital (2)
5011 - Woodville South - The Queen Elizabeth Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
6009 - Nedlands - Linear Clinical Research (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2139 - Concord - Concord Repatriation General Hospital (1)
3066 - Epping - Northern Hospital (1)
3199 - Frankston - PASO Medical (1)
6009 - Nedlands - One Clinical Research (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2217 - Kogarah - St George Private Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
Cancer Type
Cancer
Solid tumour
Exocrine pancreatic cancer
Gastrointestinal cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Pancreatic adenosquamous carcinoma
Colorectal cancer
Lower gastrointestinal cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy